Category: District of Delaware
-
Moderna and GlaxoSmithKline settle mRNA vaccine dispute with cross-license; “not obligated to make payments”
The agreement settles pending litigation in the United States and Europe.
-
$9M attorney fees award reversed by Federal Circuit for Myriad-plus proof of unpatentability
The panel concluded that while the plaintiff “ultimately did not prevail, it cannot be said that the substantive strength of its… position was so exceptionally meritless” as to justify the fees award.
-
Disney hit with fresh U.S. patent infringement action by Advance VDP licensor Tagivan II
Disney is facing yet another patent infringement case, this time by Tagivan LLC, in the U.S. District Court for the District of Delaware.
-
Qualcomm, Arm each claim victory in architecture licensing standoff; jury awards $2 damages
The two chipmakers have been engaged in a long-running contractual dispute over use of Arm’s processor architecture IP.
-
Disney hit with Delaware complaint from ETRI over video coding SEPs
ETRI claims that Disney was repeatedly contacted by Access Advance to take a (F)RAND license to the VDP pool, which would cover the asserted patents.
-
Janssen wins landmark preliminary injunction in District of Delaware
The U.S. District Court has issued a preliminary injunction against Accord BioPharma and Bio- Thera Solutions over the alleged infringement of 17 of Janssen’s patents related to golimumab, a key ingredient in its drugs used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
-
Federal Circuit distinguishes impossibility from indefiniteness, affirms Samsung invalidity win on enablement grounds
The Federal Circuit upheld Samsung’s invalidity win, but shifted the basis from indefiniteness to lack of enablement.
-
Mylan seeks declaratory judgment against Novo Nordisk over newly issued Wegovy patent, aiming to preempt a new Delaware lawsuit
Mylan has asked a Delaware court to declare a newly issued Novo Nordisk Wegovy patent invalid and not infringed, opening a new front in their long-running Hatch-Waxman fight over generic semaglutide.
-
Solar patent wars: GameChange hits back at Nextpower in District of Delaware over solar tracking technology
The battle opens another front in the complex web of patent disputes over solar energy technologies.